OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
OKYO Pharma Limited has commenced a Phase 2 clinical trial for its drug OK-101, targeting neuropathic corneal pain (NCP), a rare and debilitating eye condition lacking FDA-approved treatments. The trial aims to enroll 48 participants and follows promising results from a previous trial where OK-101 showed significant improvements in ocular pain associated with dry eye disease. This development marks a crucial step for OKYO as it continues to advance its innovative therapies for eye conditions in the pharmaceutical market.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.